Metastasierung beim Mammakarzinom trotz histologisch negativem Wächterlymphknoten

Summary

The sentinel lymph node (SLN) is of considerable prognostic relevance, because extended lymph node dissection may not be performed in patients presenting with histologically negative SLN. The aim of this study was to prove the prognostic value of the SLN-concept in these patients in long term follow-up. Patients, methods: The clinical follow-up of 202 women with histologically proven breast cancer and metastatically uninvolved (negative) SLN, as determined using Tc-99m-nanocolloid, was observed for a mean period of 43.4 months. Histological examination included standard methods (HE-Test) and special histochemical techniques (antibodies against cytokeratin). All patients underwent clinical examinations and mamography according a standardised schema; other procedures like ultrasound examination, routine blood tests, and chest X-ray scans were performed in patients considered doubtful after clinical examination or mamography. Results: Despite of negative SLNfindings in 14/202 patients (6.9%) metastases were found after a mean time period of 35.9 months. 4 patients showed local relapses, 3 patients presented with regional lymph node recurrences in the previously mapped (negative) SLN-basin, and 7 Patients developed distant metastases outside the primary lymphatic basin. Conclusion: In patients negative on SLN-biopsy the axillary lymphnode-recurrence-rate was low; in 3/202 patients (1.5%) a progression in the SLN-basin could be assessed, being real concept failures. Our results underline that there is no evidence to question this concept in patients presented with clinically metastatically uninvolved early stage of breast cancer.

Zusammenfassung

Weil der Wächterlymphknoten (SLN) beim Mammakarzinom den Befall nachgeschalteter Lymphknotengruppen reflektiert, erfolgt bei histologisch unauffälligem SLN primär keine regionale Lymphknoten-Dissektion. Ziel dieser klinischen Verlaufsuntersuchung war es, die prognostische Aussage dieses Konzeptes im Langzeit-Verlauf zu prüfen. Patientinnen und Methoden: Der klinische Verlauf von 202 Patientinnen mit gesichertem Mamma-Karzinom und histologisch unauffälliger (negativer) SLN-Exstirpation, detektiert durch ^99mTc-Nanocolloid, wurde über einen mittleren Zeitraum von 43,4 Monaten verfolgt. Die histo logische Aufarbeitung umfasste Standardmethoden (HE-Färbung) sowie spezielle immun histochemische Techniken (Zytokeratin-Antikörper-Untersuchung). Alle Patientinnen unterzogen sich klinischen und Mammographie-Untersuchungen nach einem standardisierten Schema; andere Verfahren wie Ultraschall-Untersuchung, Routine-Blut-Teste und Röntgen-Untersuchungen des Thorax wurden bei suspekten klinischen oder Mammo graphie-Befunden durchgeführt. Ergebnisse: Trotz negativem SLN zeigten 14/202 Patientinnen (6,9%) nach einer mittleren Beobachtungszeit von 35,9 Monaten ein Lokalrezidiv und/oder eine Metastasierung. Vier Patientinnen zeigten ein Lokalrezidiv, bei drei Patientinnen konnte eine Lymphknoten-Metastasierung in der (negativen) SLN-Abflussregion gesichert werden und bei 7 Patientinnen entwickelten sich Fernmetastasen außerhalb des zuvor detektierten (negativen) primären Lymph abflussgebietes. Schlussfolgerung: Die axilläre Lymphknoten-Rezidiv-Rate nach negativer SLN-Exstirpation war niedrig; bei 3/202 Patientinnen (1,5%) konnte eine Progression in der SLN-Abflussregion, im Sinne echter Konzeptversager, beobachtet werden. Unsere Daten unterstreichen, dass derzeit keine Notwendigkeit besteht das SLN-Konzept beim präoperativ klinisch nicht metastasierten Frühstadium

Keywords

Sentinel lymph node - breast cancer - lymph scintigraphy - intraoperative evaluation - falsenegative

Schlüsselwörter

Wächterlymphknoten - Mammakarzinom - Lymphszintigraphie - intraoperative Evaluation - falsch-negativ

^* Die Patientinnendaten sowie die statistische preprint online: February 7, 2013 Auswertung sind Teil der Dissertationsschrift von Frau Melanie Meyer.

• Literatur

• 1 Brenner W, Ostertag H, Czech N. et al. Lymph scintigraphy and pre- and intraoperative gamma probe measurements for localization of sentinel lymph nodes (SLN) in breast cancer. Nuklearmedizin 2000; 39: 82-87.
• 2 Dalus K, Reitsamer R, Holzmannhofer J. et al. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients. Nuklearmedizin 2011; 50: 33-38.
• 3 Diest van PJ, Peterse HL, Borgstein PJ. et al. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999; 26: 43-49.
• 4 Deurzen van CH, Hobbelink MG, van Hillegersberg R, van Diest PJ. Is there an indication for sentinel node biopsy in patients with ductal carcinoma in situ of the breast? A review. Eur J Cancer 2007; 43: 993-1001.
• 5 Giuliano AE, Kirgan DM, Guenther JM. et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-401.
• 6 Giuliano AE, Haigh PI, Brennan MB. et al. Prospective observational study of sentinel lymph-adenectomy without further axillary dissection in patients with sentinel node negative breast cancer. J Clin Oncol 2000; 18: 2553-2559.
• 7 Holl G, Stöcklein R, Dorn R. et al. Influence of the injection technique on the false negative rate of SLNE in multifocal breast cancer. Nuklearmedizin 2008; 47: 216-219.
• 8 Hunt KK, Ballman KV, McCall LM. et al. Factors Associated With Local-Regional Recurrence After a Negative Sentinel Node Dissection: Results of the ACOSOG Z0010 Trial. Ann Surg 2012; 256: 428-436.
• 9 Kim HJ, Chang MA, Hong SJ. et al. Result of sentinel lymph node biopsy using radioisotope in clinically lymph node negative breast cancer. J Breast Cancer 2007; 10: 141-146.
• 10 Kim HJ, Son BH, Park EW. et al. Axillary recurrence after negative sentinel lymph node biopsy. Breast Cancer Res Treat 2009; 114: 301-305.
• 11 Koizumi M, Makita M, Yoshimoto M. et al. Indications for sentinel lymph node biopsy in patients with breast cancer: Retrospective and simulation analyses. Jpn J Clin Oncol 2002; 32: 517-524.
• 12 Krag DN, Weaver DL, Alex JC. et al. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2: 335-340.
• 13 Kühn T, Bembenek A, Büchels H. et al. Sentinel node biopsy in breast cancer. Nuklearmedizin 2004; 43: 4-9.
• 14 Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am 2003; 83: 931-942.
• 15 Miltenburg DM, Miller C, Karamlou TB. et al. Metaanalysis of sentinel lymph node biopsy in breast cancer. J Surg Res 1999; 84: 138-142.
• 16 Nagashima T, Sakakibara M, Nakano S. et al. Sentinel node micrometastasis and distant failure in breast cancer patients. Breast Cancer 2006; 13: 186-191.
• 17 Naik AM, Fey J, Gemignani M. et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow- up study of 4008 procedures. Ann Surg 2004; 240: 462-471.
• 18 Newman LA, Hunt KK, Cuchholz T. et al. Presentation, management and outcome of axillary recurrence from breast cancer. Am J Surg 2000; 180: 252-256.
• 19 Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A. et al. Follow up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001; 77: 165-170.
• 20 Schrenk P, Rehberger W, Shamiyeh A, Wayand W. Sentinel node biopsy for breast cancer: does the number of sentinel nodes removed have an impact on the accuracy of finding a positive node?. J Surg Oncol 2002; 80: 130-136.
• 21 Taras AR, Hendrickson NA, Lowe KA. et al. Recurrence rates in breast cancer patients with falsenegative intraoperative evaluation of sentinel lymph nodes. Am J Surg 2010; 199: 625-628.
• 22 Veronesi U, Viale G, Paganelli G. et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010; 251: 595-600.
• 23 Vogt H, Schmidt M, Bares R. et al. Procedure guideline for sentinel lymph node diagnosis. Nuklearmedizin 2010; 49: 167-172.
• 24 Weiss M, Gildehaus FJ, Brinkbäumer K. et al. Lymph kinetics with technetium-99m labeled radiopharmaceuticals - Animal studies. Nuklearmedizin 2005; 44: 156-165.
• 25 Wely van BJ, Smidt ML, de Kievit IM. et al. Falsenegative sentinel lymph node biopsy. Br J Surg 2008; 95: 1352-1355.
• 26 Zavagno G, De Salvo GL, Scalco G. et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 2008; 247: 207-213.
• 27 Zervos EE, Badgwell DB, Abdessalam SF. et al. Selective analysis of the sentinel node in breast cancer. Am J Surg 2001; 182: 372-376.